CD34 and hematologic disorder: This strategy was initially studied in patients with high risk hematologic malignancies undergoing MSD HCT, utilizing a 2-step selection procedure with a CD34+ selection of stem cells (a minor subset of which expresses CD45RA) followed by depletion of CD45RA+ cells from the CD34− fraction.